Harpoon Therapeutics, Inc. (HARP)
| Market Cap | 78.07M |
| Revenue (ttm) | 20.55M |
| Net Income (ttm) | -75.32M |
| Shares Out | 33.08M |
| EPS (ttm) | -3.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,754,036 |
| Open | 2.10 |
| Previous Close | 2.00 |
| Day's Range | 2.10 - 2.79 |
| 52-Week Range | 1.73 - 22.74 |
| Beta | 1.10 |
| Analysts | Buy |
| Price Target | 14.79 (+526.7%) |
| Earnings Date | May 12, 2022 |
About HARP
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II cl...
Financial Performance
In 2021, HARP's revenue was $23.65 million, an increase of 35.60% compared to the previous year's $17.44 million. Losses were -$116.72 million, 133.9% more than in 2020.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for HARP stock is "Buy." The 12-month stock price forecast is 14.79, which is an increase of 526.69% from the latest price.
News
Best Penny Stocks to Buy This Week? 3 to Watch Right Now
Check these penny stocks out for your watchlist right now The post Best Penny Stocks to Buy This Week? 3 to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...
Harpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Misses Revenue Estimates
Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of -29.17% and 47.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Harpoon Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financial...
Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small...
HPN328, Harpoon's DLL3-targeting T cell engager, to be evaluated in combination with anti-PD-L1 antibody in patients with small cell lung cancer HPN328, Harpoon's DLL3-targeting T cell engager, to be ev...
Harpoon Therapeutics Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by ...
TriTAC-XR demonstrates extended release mechanism that confirms accumulation of active drug which improves therapeutic index TriTAC-XR demonstrates extended release mechanism that confirms accumulation ...
Harpoon Therapeutics Announces Leadership Change
SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that N...
Harpoon Therapeutics to Participate in Canaccord Genuity Horizons in Oncology Virtual Conference
SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that m...
Harpoon Therapeutics Discontinues Its Once Lead Prostate Cancer Candidate
Harpoon Therapeutics Inc (NASDAQ: HARP), in its Q4 FY21 earnings results, has given up on its onetime lead prospect HPN424. "We are focusing our resources on portfolio programs that show promising acti...
Harpoon Therapeutics, Inc. (HARP) Reports Q4 Loss, Lags Revenue Estimates
Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of -43.48% and 38.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the ...
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financi...
Harpoon Therapeutics Granted Orphan Drug Designation for HPN328 for Treatment of Small Cell Lung Cancer
SOUTH SAN FRANCISCO, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that t...
Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217
SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that t...
Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that ma...
Wall Street Analysts See a 274% Upside in Harpoon Therapeutics, Inc. (HARP): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 274.4% in Harpoon Therapeutics, Inc. (HARP). While the effectiveness of this highly sought-after metric is questi...
Harpoon Therapeutics Provides Pipeline Development Milestones for 2022
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today provided a pipeli...
Harpoon Therapeutics Provides Pipeline Update for TriTAC® Clinical Programs and T Cell Engager Platforms
SOUTH SAN FRANCISCO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today provided a pipeli...
Harpoon Shares Jump After Early Data From BCMA-Targeting Myeloma Candidate At ASH Meet
Harpoon Therapeutics Inc (NASDAQ: HARP) presented a poster with interim data from the ongoing dose-escalation portion of the Phase 1/2 trial for HPN217 in patients with relapsed/refractory multiple myel...
Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for ...
Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 µg/week cohort with 8 disease evaluable patients with relapsed/refractory multiple myeloma
Harpoon Therapeutics to Host Pipeline Update Call and Webcast on December 13, 2021
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it...
Harpoon Therapeutics, Inc. (HARP) Reports Q3 Loss, Lags Revenue Estimates
Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 1.92% and -29.75%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the ...
Harpoon Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today report...
Harpoon Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announ...
Harpoon Therapeutics to Present at the 63rd ASH Annual Meeting and Exposition
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announ...
Harpoon Therapeutics, Inc. (HARP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Harpoon Therapeutics, Inc. (HARP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harpoon Therapeutics Announces Change to Management Team and Board of Directors
Julie Eastland Appointed President and Chief Executive Officer